Intellia Therapeutics (NASDAQ:NTLA) Given “Market Outperform” Rating at Citizens Jmp

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “market outperform” rating reissued by analysts at Citizens Jmp in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $30.00 price target on the stock. Citizens Jmp’s target price would indicate a potential upside of 122.42% from the company’s previous close.

Several other research firms also recently weighed in on NTLA. Morgan Stanley lifted their price target on shares of Intellia Therapeutics from $11.00 to $15.00 and gave the company an “equal weight” rating in a research note on Monday, April 27th. Truist Financial raised shares of Intellia Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of Intellia Therapeutics in a research note on Monday. Bank of America reaffirmed a “neutral” rating on shares of Intellia Therapeutics in a research report on Monday, March 2nd. Finally, reaffirmed a “buy” rating on shares of Intellia Therapeutics in a research note on Tuesday, March 3rd. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $20.46.

Intellia Therapeutics Stock Performance

Shares of NTLA stock traded up $1.38 during trading hours on Monday, hitting $13.49. 2,150,354 shares of the company were exchanged, compared to its average volume of 5,486,125. The company has a 50 day simple moving average of $13.60 and a two-hundred day simple moving average of $12.32. The firm has a market cap of $1.88 billion, a P/E ratio of -3.81 and a beta of 1.92. Intellia Therapeutics has a fifty-two week low of $7.95 and a fifty-two week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.11. The company had revenue of $15.05 million for the quarter, compared to the consensus estimate of $13.81 million. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. During the same quarter in the previous year, the company earned ($1.10) EPS. As a group, sell-side analysts expect that Intellia Therapeutics will post -3.18 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Seven Fleet Capital Management LP acquired a new position in shares of Intellia Therapeutics during the first quarter valued at about $404,000. Avidity Partners Management LP acquired a new stake in shares of Intellia Therapeutics in the 1st quarter worth about $962,000. Wellington Grp LLC raised its holdings in shares of Intellia Therapeutics by 50.9% in the 1st quarter. Wellington Grp LLC now owns 46,297 shares of the company’s stock worth $594,000 after acquiring an additional 15,620 shares during the last quarter. Bank of America Corp DE lifted its position in Intellia Therapeutics by 11.2% in the 1st quarter. Bank of America Corp DE now owns 1,381,703 shares of the company’s stock valued at $17,713,000 after acquiring an additional 139,325 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in Intellia Therapeutics during the 1st quarter valued at about $250,000. 88.77% of the stock is owned by institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.